Abstract
Organ transplantation is a critical treatment for end-stage organ failure, but long-term graft survival remains suboptimal due to ischemia-reperfusion injury (IRI) and transplant rejection. The immune microenvironment, especially macrophages, plays a key role in these processes. Various forms of regulated cell death (apoptosis, autophagy, pyroptosis, ferroptosis, necroptosis) in macrophages significantly influence transplant rejection by mediating cellular communication and shaping the immune microenvironment. Apoptosis, pyroptosis, ferroptosis and necroptosis in macrophages exacerbate graft rejection while autophagy in macrophages protects against transplant rejection by reducing inflammation. This paper reviews the specific molecular mechanisms of macrophage regulated cell death, their impact on the IRI and transplant rejection, thus further provide potential therapeutic target for improving transplant outcomes.
Introduction: The Macrophage as a Rheostat for Graft Survival
While modern surgical techniques and advanced immunosuppressants have pushed one-year graft survival rates above 90%, the long-term outlook for transplant recipients remains a significant clinical challenge. Two primary obstacles frequently derail long-term success: Ischemia-Reperfusion Injury (IRI)—the damage sustained when blood flow returns to a donor organ—and chronic rejection.
At the heart of both processes is the macrophage. These versatile immune cells are not passive observers; they actively respond to the stress of transplantation by undergoing various forms of Regulated Cell Death (RCD). Depending on the specific "mode of death," a macrophage can either act as a pro-inflammatory beacon, recruiting aggressive immune cells to attack the graft, or quietly promote immune tolerance and tissue repair. Understanding these pathways is essential for developing therapies that extend graft survival from years to decades.
Mechanisms of Regulated Cell Death in Macrophages
Research has identified five major types of RCD that play distinct roles in the transplant environment. These can be broadly categorized into "inflammatory" pathways—which generally exacerbate rejection—and "protective" pathways.
- Apoptosis: Traditionally viewed as a "quiet" or non-inflammatory form of programmed cell suicide, apoptosis in macrophages can still contribute to graft rejection by releasing specific cytokines.
- Autophagy: This is a self-recycling mechanism that often acts as a survival pathway. In the context of transplantation, macrophage autophagy is largely protective, as it suppresses the inflammasome and reduces overall inflammation.
- Pyroptosis: A highly inflammatory, "explosive" form of death characterized by the formation of membrane pores and the release of pro-inflammatory cytokines like IL-1β.
- Ferroptosis: An iron-dependent form of oxidative death. During IRI, iron levels spike, triggering lipid peroxidation that destroys macrophage membranes.
- Necroptosis: A programmed form of necrosis that mimics accidental cell bursting, releasing Damage-Associated Molecular Patterns (DAMPs) that trigger intense immune responses.
The signaling pathways for these death modes are often interconnected. For example, the master regulator TNF-α can trigger either apoptosis or necroptosis depending on the activity of Caspase-8. This "molecular cross-talk" means that blocking one pathway might inadvertently cause a cell to switch to a more inflammatory mode of death. Furthermore, the way a macrophage dies influences the polarization of the surrounding macrophage population, shifting them toward either a pro-inflammatory (M1) or pro-repair (M2) state.
Therapeutic Implications and Future Directions
The identification of these specific death pathways provides a roadmap for new therapeutic interventions. Several drugs targeting these mechanisms are already in clinical use or undergoing testing:
- mTOR Inhibitors: Drugs like Everolimus modulate autophagy and are already approved for clinical use.
- TNF-α Blockers: Agents like Adalimumab target the upstream signals for apoptosis and necroptosis.
- Experimental Inhibitors: Necrostatin-1 is being investigated to block necroptosis by inhibiting the RIPK1 protein. Disulfiram, traditionally used for alcohol use disorder, is being repurposed in preclinical studies to block pyroptosis by preventing membrane pore formation.
- Targeting Ferroptosis: Inhibitors like Ferrostatin-1 have shown significant promise in animal models by mitigating the iron-dependent damage seen during IRI.
Despite these advances, several challenges remain. The transplant microenvironment is incredibly complex, with multiple forms of RCD likely occurring simultaneously. Future research must focus on organ-specific effects and explore emerging death modes such as cuproptosis (copper-dependent death). Translating these promising preclinical findings into rigorous human clinical trials is the next vital step toward ensuring the long-term health of transplanted organs.
Summary updated